A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Blood 2017 129: 424–47.īurnett AK, Milligan D, Prentice AG, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (accessed 25 April 2018).ĭohner H, Estey E, Grimwade D, et al. Cancer stat facts: leukemia-acute myeloid leukemia (AML). Surveillance, Epideiomolgy and End Results Program. Lyon, France: International Agency for Research on Cancer (IARC), 2017. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In this review, we present clinical data from the pivotal trials evaluating venetoclax-based combinations in older patients ineligible for intensive chemotherapy, and provide practical recommendations for the prevention and management of adverse events associated with venetoclax.Īcute myeloid leukemia older patients treatment venetoclax. Appropriate prophylactic measures can reduce the risk of venetoclax-induced tumor lysis syndrome. A bone marrow assessment after the first cycle of treatment is critical to determine dosing and timing of subsequent cycles, as most patients will achieve their best response after one cycle. The most common adverse events with venetoclax combinations are gastrointestinal symptoms, which are primarily low grade and easily manageable, and myelosuppression, which may require delays between cycles, granulocyte colony-stimulating factor (G-CSF) administration, or decreased duration of venetoclax administration per cycle. In the pivotal clinical trials evaluating venetoclax either in combination with LDAC or with HMA, the rates of complete remission (CR) plus CR with incomplete hematological recovery were 54% and 67%, respectively and the median overall survival (OS) was 10.4 months and 17.5 months, respectively, comparing favorably with outcomes in clinical trials evaluating single-agent LDAC or HMA. Is now approved by the US Food and Drug Administration for this indication.

The oral B-cell lymphoma 2 inhibitor, venetoclax, Venetoclax, an oral B-cell lymphoma 2 (BCL2) inhibitor, is now approved by the USA Food and Drug Administration (FDA) in combination with LDAC or HMA in older AML patients ineligible for intensive chemotherapy.

Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating agents (HMA) azacitidine and decitabine, which have historically provided only short-lived and modest benefits. Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy.

Guillaume rochard